Skip to main content

Peer Review reports

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

Original Submission
21 Apr 2012 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
8 Nov 2012 Editorially accepted
8 Nov 2012 Article published 10.1186/1741-7015-10-135

You can find further information about peer review here.

Back to article page